DM addressed that at the 2018 AGM:

Q: Don, if Zenith Epigenetics is sold being a subsidiary of Zenith Capital is that a material change to Zenith Capital and does it require a shareholder vote?

A   No. So the sole owner of Zenith Epigenetics is Zenith Capital Corporation. And the existing plan as always has been, at the time of an M&A transaction, should that be what it is, we would in parallel or just before dividend the  Zenith Epigenetics shares out to the corresponding shareholders. And we don’t want to do that now because it’s a taxable event. And I don’t want to pay my share of the taxes yet, not until there’s money to pay the tax.

Q: Don what is your preferred deal structure if somebody like J&J or Pfizer steps up and either wants to buy the drug or the whole company.

A: Cash on the barrel? As far as preferred structure we don’t need - I mentioned J&J and Pfizer because they own those two drugs. But that doesn’t have to be who buys the follow-on drug. It could be anybody as long as they have a solid oncology program and good sales force that type of approach, but my preferred would actually be a straight M&A transaction. In order to sell 3694, what would be required is only three of the patents held by Zenith be left in Zenith Epigenetics. Everything else could be left in Zenith Capital Corporation. So with those there patents they would have what they need to run the entire program, but not necessarily take all of the IP. 

(from imtesty's transcription)